Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Company reports $8.8M Q2 loss, provides clinical update
September 5th, 2004
Emisphere Technologies, Inc., (EMIS) announced results for the second quarter ended June 30, 2004. The company also highlighted its progress in development programs using its proprietary eligen drug-delivery technology. Emisphere reported a net loss of $8.8 million, or $0.48 per share, for the quarter ended June 30, 2004, as compared to a net loss of $11.4 million, or $0.63 per share for the quarter ended June 30, 2003. Total operating expenses were $7.7 million for the 2004 second quarter, a decrease of $3.0 million, or 28%, compared to the same period last year. Total operating expenses include research and development costs of...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
